Clinical trials for Lung cancer

285 currently recruiting clinical trials
Phase 3 Lung cancer #NCT06472245 #2023-509340-10-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Immunotherapy
Excluded genetic anomalies
ALK EGFR ROS-1
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
29 recruiting sites
OSE Immunotherapeutics
Phase 3 Lung cancer #NCT04928846 #2023-505749-14-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required histologic sub types
Non-squamous NSCLC
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
MET
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Immunotherapy Chemotherapy Targeted therapy
Excluded genetic anomalies
EGFR
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive Antibody Drug Conjugates (ADC)
12 recruiting sites
Abbvie
Phase 3 Lung cancer #NCT04790253
Required histologic types
SCLC (Small Cell Lung Cancer)
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Chemotherapy
Required previous treatments at advanced or metastatic stage
Chemotherapy
16 recruiting sites
EORTC - Organisation Européenne pour la Recherche et le Traitement du Cancer
Phase 3 Lung cancer #NCT06284317 #2023-508773-82-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Localized Locally Advanced
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded genetic anomalies
ALK EGFR
Excluded previous treatments at localized stage
Surgery Immunotherapy Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Surgery Immunotherapy Chemotherapy
4 recruiting sites
ETOP IBCSG Partners Foundation
Phase 3 Lung cancer #NCT06452277 #2024-511319-91-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required histologic sub types
Non-squamous NSCLC
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
HER2
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded previous treatments at advanced or metastatic stage
Targeted therapy
14 recruiting sites
Bayer
Phase 3 Lung cancer #NCT05920356 #2022-501863-41-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required histologic sub types
Non-squamous NSCLC
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
KRAS G12C
Required PDL1 statuses
PDL1 Negative (< 1%)
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded previous treatments at localized stage
Targeted therapy
Excluded previous treatments at advanced or metastatic stage
Immunotherapy Chemotherapy Targeted therapy Car-T Bispecific T-cell engager antibodies Antibody Drug Conjugates (ADC)
27 recruiting sites
Amgen
Phase 3 Lung cancer Colon cancer Rectal cancer Pancreas cancer Sarcoma and GIST #NCT06332274 #2023-503316-33-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer) Soft tissue sarcoma
Required disease stage
Localized Locally Advanced
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Surgery Chemotherapy
Required previous treatments at advanced or metastatic stage
Surgery Chemotherapy
Excluded genetic anomalies
EGFR
Excluded previous treatments at localized stage
Immunotherapy
Excluded previous treatments at advanced or metastatic stage
Immunotherapy
4 recruiting sites
Gustave Roussy, Campus du cancer, Grand Paris
Phase 3 Lung cancer #NCT06119581 #2023-503412-33-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
KRAS G12C
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded genetic anomalies
BRAF EGFR HER2 MET NTRK-1/2/3 RET ROS-1
Excluded previous treatments at advanced or metastatic stage
Immunotherapy Chemotherapy Targeted therapy
18 recruiting sites
Eli Lilly et compagnie
Phase 3 Lung cancer #NCT06881784 #2024-518154-16-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
Other KRAS HRAS KRAS G12C KRAS non G12C KRAS G12D NRAS
Required number of previous lines of therapy for current stage of disease
1 2
Required previous treatments at advanced or metastatic stage
Immunotherapy Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
16 recruiting sites
Revolution Medicines, Inc.
Phase 3 Lung cancer #NCT06623422 #2023-506327-29-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Localized Locally Advanced
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded genetic anomalies
ALK EGFR
Excluded previous treatments at localized stage
Immunotherapy
Excluded previous treatments at advanced or metastatic stage
Immunotherapy
7 recruiting sites
Merck Sharp & Dohme LLC